AM-281 synthetic, CB1 antagonist and inverse agonist

 

Design and Synthesis of the CB1 Selective Cannabinoid Antagonist AM281: A Potential Human SPECT Ligand                  (link to PDF – 1999)    http://www.aapsj.org/view.asp?art=ps010204

 

[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients.                                                               (abst – 2004)  http://www.ncbi.nlm.nih.gov/pubmed/15110734

 

Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats                              (full – 2005)  http://bja.oxfordjournals.org/content/94/5/563.full

 

CARDIOVASCULAR Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats (abst – 2005)                           http://academic.research.microsoft.com/Paper/11905213

 

The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors                      (abst – 2005)       http://www.sciencedirect.com/science/article/pii/S0014299905013178

 

Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine.

(abst – 2006)           http://www.ncbi.nlm.nih.gov/pubmed/17072693

 

The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.                                        (full – 2009)      http://www.fasebj.org/content/23/1/183.long

 

GPR55 ligands promote receptor coupling to multiple signalling pathways.  (full – 2010)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931561/?tool=pubmed

 

Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype                            (full – 2010)  http://ajpgi.physiology.org/content/299/1/G63.full?sid=fc6948f0-78cf-405c-981b-afaa05ee417c

 

Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. (full – 2010)                               http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930808/?tool=pubmed

 

Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.                                 (full – 2012)  http://www.jbc.org/content/early/2012/07/11/jbc.M112.346296.full.pdf+html

 

Early Endogenous Activation of CB1 and CB2 Receptors after Spinal Cord Injury Is a Protective Response Involved in Spontaneous Recovery                        (full – 2012)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496738/

 

The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.       (full – 2012)  http://www.jbc.org/content/early/2012/11/16/jbc.M112.364109.long

 

Regulation of endocannabinoid release by G proteins: A paracrine mechanism of G protein-coupled receptor action.   (abst – 2012)                                             http://www.ncbi.nlm.nih.gov/pubmed/22075205

 

Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells.                                      (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22842590

 

Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats. (abst – 2012)                          http://www.ncbi.nlm.nih.gov/pubmed/22959964

 

Cannabinoid Receptors as Therapeutic Targets for Dialysis-Induced Peritoneal Fibrosis. (abst – 2013)                           http://www.ncbi.nlm.nih.gov/pubmed/23296044

Share a link for